|
|
 |
|
Viewing report
|
|
|
|
Abbott Laboratories Dec 11
Standard & Poors, Dec 2011
Abstract
Well-established positions in a broad range of health care markets; Strong product portfolio, driven by the success of Humira and the Xience stent platform; Limited exposure to patent expirations over the next two years; and Conservative financial policies. Willingness to aggressively pursue acquisitions to bolster the business portfolio; and Near-term pipeline is a little light in high-potential prospects. The 'AA' long-term and corporate credit ratings and 'A-1+' commercial paper rating on Abbott Park, Ill.-based Abbott Laboratories were placed on CreditWatch with negative implications on Oct. 19, 2011, on its decision to separate into two companies, one in diversified medical products and the other in research-based pharmaceuticals. The CreditWatch listing reflects the weaker business risk profile derived from a smaller and...
Companies mentioned in this report are: Abbott Laboratories
Action: Review
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
Research Type: Full Analysis
|
|
|
|
